Development Pipeline

Today, our research efforts are dedicated to advancing a diverse pipeline of innovative therapies for solid tumors and blood-related cancers.
Learn about our development programs by selecting an agent below or click to explore our interactive pipeline.

Brentuximab vedotin

an antibody–drug conjugate directed to CD30 being investigated in certain lymphomas and solid tumors

  • Phase 2
  • Phase 3

View Program

Enfortumab vedotin

an investigational antibody-drug conjugate directed to Nectin-4

  • Phase 1
  • Phase 2
  • Phase 3

View Program

Tucatinib

a highly selective small molecule tyrosine kinase inhibitor being investigated in multiple HER2-overexpressed/amplified and HER2-mutated cancers

  • Phase 2
  • Phase 3

View Program

Tisotumab vedotin

an investigational antibody-drug conjugate directed to tissue factor

  • Phase 2
  • Phase 3

View Program

Disitamab vedotin

an investigational antibody-drug conjugate directed to HER2

  • Phase 1
  • Phase 2
  • Phase 3

View Program

SGN-B6A

an investigational antibody-drug conjugate directed to integrin beta-6 (IB6)

  • Phase 1
  • Phase 3

View Program

SGN-35T

an investigational CD30-directed, next generation antibody-drug conjugate with novel tripeptide linker

  • Phase 1

View Program

SGN-B7H4V

an investigational antibody-drug conjugate directed to B7-H4

  • Phase 1

View Program

SGN-PDL1V

a novel, investigational antibody–drug conjugate directed to PD-L1

  • Phase 1

View Program

SGN-CEACAM5C

an investigational topoisomerase I inhibitor antibody-drug conjugate targeting CEACAM5

  • Phase 1

View Program

SGN-BB228

an investigational costimulatory bispecific molecule composed of a CD228-directed antibody and 4-1BB-directed Anticalin® proteins

  • Phase 1

View Program

SGN-EGFRd2

an investigational bispecific gamma delta (γδ)-T cell engager directed to EGFR

  • Phase 1

View Program

SEA-CD70

an investigational sugar-engineered antibody directed to CD70

  • Phase 1

View Program